Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AIM ImmunoTechAIM +1.84%22 Equity-to-Asset is 0.61 as of Jun. 2026, which is 5% below its 10-year median of 0.64. GuruFocus rates AIM with a GF Score™ of 22/100 and a GF Value™ of $0.91 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, AIM ImmunoTech ranks worse than 57.7% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. AIM ImmunoTech's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $7.74 Mil. AIM ImmunoTech's Total Assets for the quarter that ended in Jun. 2026 was $12.73 Mil.
Therefore, AIM ImmunoTech's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.61.
The historical rank and industry rank for AIM ImmunoTech's Equity-to-Asset or its related term are showing as below:
AIM'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.69 Med: 0.64 Max: 0.99
Current: 0.61
During the past 13 years, the highest Equity to Asset Ratio of AIM ImmunoTech was 0.99. The lowest was -1.69. And the median was 0.64.
AIM's Equity-to-Asset is ranked worse than 57.7% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs AIM: 0.61
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
AIM ImmunoTech Equity-to-Asset Related Terms
AIM ImmunoTech Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for AIM ImmunoTech's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM vs NIKI, PMCB, PCSA: Equity-to-Asset Comparison
For the Biotechnology subindustry, AIM ImmunoTech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM ImmunoTech Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where AIM ImmunoTech's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
AIM ImmunoTech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM ImmunoTech (AIM) has a Equity-to-Asset of 0.61 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on AIM ImmunoTech and its competitors. This is near median its historical median of 0.64. According to the industry distribution chart, AIM ImmunoTech ranks #817 out of 1416 companies in the Biotechnology industry, placing it in the top 57.7%.
Is AIM ImmunoTech's Equity-to-Asset too high?
AIM ImmunoTech's current Equity-to-Asset of 0.61 is near median its 10-year median of 0.64. The Biotechnology industry median Equity-to-Asset is 0.68. AIM ImmunoTech's value of 0.61 is 10.3% below this industry median. Based on the distribution chart, AIM ImmunoTech ranks #817 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AIM ImmunoTech has a GF Score™ of 22/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Equity-to-Asset compare to NIKI and PMCB?
According to the Biotechnology industry distribution chart, AIM ImmunoTech ranks #817 out of 1416 companies for Equity-to-Asset. This places AIM ImmunoTech in the lower half of its industry. The industry median Equity-to-Asset is 0.68. AIM ImmunoTech's value of 0.61 is 10.3% below this benchmark. While the company's 10-year median is 0.64 vs. the industry median of 0.68, AIM ImmunoTech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AIM ImmunoTech's current Equity-to-Asset of 0.61 is 10.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on AIM ImmunoTech and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AIM ImmunoTech's current Equity-to-Asset is 0.61, which is near median its own 10-year median of 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $0.91, compared to a current price of $0.24 — trading 73.8% below its estimated fair value. The current Equity-to-Asset is 0.61, which is near median its 10-year median of 0.64 and 10.3% below the Biotechnology industry median of 0.68. AIM ImmunoTech's overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current Equity-to-Asset is 0.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM ImmunoTech (AIM) Overvalued in 2026?
Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued.
The current stock price of $0.24 is trading 73.8% below its estimated GF Value™ of $0.91.
GuruFocus considers AIM ImmunoTech to be Possible Value Trap.
Key valuation signals for AIM:
Equity-to-Asset: 0.61 (near median its 10-year median of 0.64)
GF Value™: $0.91 vs. price of $0.24 (73.8% below fair value)
Industry Position: 10.3% below the Biotechnology median (#817 of 1416)
No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
22GF Score
Get the complete analysis for AIM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIM has been successfully added to your 
